Seres Therapeutics Inc (NASDAQ:MCRB) traded at $0.91 at close of the session on Monday, April 29, made an upward move of 10.18% on its previous day’s price.
Looking at the stock we see that its previous close was $0.82. In terms of its 52-week price range, MCRB has a high of $6.65 and a low of $0.54. The company’s stock has gained about 17.43% over that past 30 days.
Seres Therapeutics Inc has a market cap of $137.27 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.34, with the EPS growth for the year raised at -$1.14 for 2024 and -$0.8 for next year. These figures represent -28.10% and 29.80% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $250k, with a high of $1.5 million. The median projection represents growth adding up to -81.90% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $1.36 million, or -98.90% down from figures reported last year.
On the other hand, looking at the outlook for the MCRB stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Looking further, we note the current price level is 30.34% off its SMA20 and 7.53% from its 50-day simple moving average. The RSI (14) is pointing at 64.37 while the volatility over the past week is 16.52% and jumps to 9.94% over the past one month. The beta value is 2.22, while the average true range (ATR) is currently pointing at 0.08.
Coming back to Seres Therapeutics Inc (NASDAQ:MCRB), we note that the average 3-month trading volume was 4.10 million. Current shares outstanding are 135.04 million.
The insiders hold 20.91% of the company’s shares while institutions hold 44.25%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -35.07% down in year-to-date price movement.
